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Abstract: SARS-CoV-2, identified in Wuhan, China, for the first time in December 2019, is a new
viral strain, which has not been previously identified in humans; it can be transmitted both by air
and via direct and indirect contact; however, the most frequent way it spreads is via droplets. Like
the other viruses belonging to the same family of coronaviruses, it can cause from mild flu-like
symptoms, such as cold, sore throat, cough and fever, to more severe ones such as pneumonia and
breathing difficulties, and it can even lead to death. Since no effective specific drug therapy has
been found yet, nor any vaccine capable of limiting the spread of this pathogen, it is important
for ways of preventing the spread of this infection to be established. The purpose of our research
was to provide a protocol to prevent the spread of SARS-CoV-2 infection in light of the limited
information related to this coronavirus. In detail, we analysed and searched targeted evidence-based
guidelines issued in the various countries affected by this epidemic up till now. In addition, we
analyzed the recommendations for the prevention and control of other epidemics caused by other
pathogens belonging to the same family of coronaviruses or others that present the same mechanisms
of transmission. General organizational measures regarding the containment and management of
the epidemiological emergency of COVID-19 have been imposed by the competent authorities for
an adequate and proportionate management of the evolution of the epidemiological situation. The
prevention and protection organizational measures therefore aim to minimize the probability of
being exposed to SARS-CoV-2. For this purpose, measures must also be taken at work to avoid
new infections or even the spread of the virus where it has already been present. Furthermore,
environmental measures are aimed at reducing the risk of transmission of SARS-CoV-2 to individuals
through contact with infected subjects, objects, equipment, or contaminated environmental surfaces.
Protective devices must be used whenever there is potentially close contact with a suspect case,
especially when the potentially infected person does not wear a surgical mask that could reduce the
spread of viruses in the environment. By adopting this specific prevention and protection measures
recommended in the workplace, it will be possible to help overcome this COVID-19 pandemic.
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1. Introduction
Coronaviruses (CoV) are a large family of positive-stranded RNA respiratory viruses. Their name
is owed to the crown-shaped tips present on their surface. Coronaviruses (CoV) are divided into four
genera, including α−/β−/γ−/δ-CoV. α- and β-CoV are able to infect mammals, while γ- and δ-CoV
tend to infect birds. Previously, six CoVs have been identified as human-susceptible viruses, among
them α-CoVs HCoV-229E and HCoV-NL63 and β-CoVs HCoV-HKU1 and HCoV-OC43, which have
low pathogenicity, causing mild respiratory symptoms similar to a common cold. The other two,
known as β-CoVs, SARS-CoV (Severe Acute Respiratory Syndrome—Coronavirus) and MERS-CoV
(Middle East Respiratory Syndrome—Coronavirus) lead to severe and potentially fatal respiratory
tract infections [1].
In December 2019, unexplained pneumonia (later named as coronavirus disease 2019, COVID-19)
broke out in Wuhan, China [2–5]. The initial patient was related to a seafood wholesale market in
Wuhan. A new type of coronavirus was isolated from human respiratory epithelial cells, which belongs
to the subgenus Sabevirus of the subfamily Coronavirus [6]. Different from the previously isolated
MERS-CoV and SARS-CoV, this virus is the seventh coronavirus that can infect humans and is named
as SARS-CoV-2 [7,8].
It is speculated that the coronaviruses circulating in pangolin, bat, and other animal species are
likely to be a “gene pool” for the generation of new recombinants [9]. Given the use of pangolins
in traditional medicine and for food, frequent human–animal interaction has been supposed the
major cause for viral cross-species transmission. The similarity analysis of SARS-CoV-2 and the
animal-origin coronaviruses has demonstrated that recombination events were likely to occur in bat-
and pangolin-origin coronaviruses [9]. In particular, the similarity between SARS-CoV-2 and the
closest bat relative is very high: all proteins in the coronavirus proteome (with the exception of ORF10)
have identities of above 85%, with full conservation of the genome length (~30 kb) [10].
The number of coronaviruses that affect people and which are known up to now, being common
all over the world, are seven. The most lethal of the known coronaviruses is MERS-CoV, which often
progresses to severe pneumonia and has an estimated mortality rate between 30% and 40%; SARS-CoV
causes fever, chills and body aches, and often progresses to pneumonia, a severe condition in which
the lungs become inflamed and fill with pus; this virus has an estimated mortality rate of 9.6%; and the
most recent, SARS-CoV-2, has an estimated mortality rate of about 2.3% (Table 1) [6].
Table 1. List of viruses belonging to human coronavirus types divided by lethality [1].
LESS LETHAL KNOWN CORONAVIRUSES MOST LETHAL KNOWN CORONAVIRUSES
229E (the alpha coronavirus) MERS-CoV (the beta coronavirus that causes theMiddle East Respiratory Syndrome)
NL63 (the alpha coronavirus) SARS-CoV (the beta coronavirus that causes theSevere Acute Respiratory Syndrome)
OC43 (the beta coronavirus) 2019 new coronavirus (SARS-CoV-2)
HKU1 (the beta coronavirus)
SARS-CoV-2 uses the same cell entry receptor—angiotensin converting enzyme II (ACE2)—as
SARS-CoV [11], producing infection that can be totally asymptomatic or can present flu-like symptoms
such as fever, cough, breathing difficulties [12]. This latter symptomatology, which is more frequent
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and severe in elderly subjects also presenting concomitant pathologies [13], is believed to occur
in young subjects too, who have a weak immune system, such as subjects undergoing acute or
chronic immunosuppressive therapy, subjects epigenetically predisposed [14], or subjects facing
excessive environmental psychophysical workload; for example, those who practice extreme or
highly-demanding activities [15], or those who have a particularly stressful work with frequent night
shifts, in which the clearly demonstrated irregularities of the normal circadian sleep–wake rhythm can
be the basis of a decrease, even if transitory, in immune defense [16].
In severe cases, COVID-19 can ultimately manifest itself as pneumonia; patients can develop
acute respiratory distress syndrome in a short period of time and die due to multiple organ failure [17].
Based upon these premises, the purpose of this review is to provide a protocol intended to prevent the
spread infection of SARS-CoV-2, in light of the few knowledge about procedures to put in place to
control critical events like the one we are experiencing. Furthermore, we also want to give an overview
regarding SARS-CoV-2 and strategies used to fight this virus.
2. Materials and Methods
We searched and analyzed targeted evidence-based guidelines issued in various countries affected
by this epidemic up to date. The recommendations for the prevention and control of other epidemics
caused by other pathogens belonging to the same family of coronaviruses or others that present
the same mechanisms of transmission also were searched and analyzed. Moreover, we checked
and analyzed different scientific papers related to pharmacological approaches, clinical assessment
of various Personal Protective Equipment (PPE) of the respiratory tract and epidemiological data
regarding this virus. In detail, we looked into all the best reports of the World Health Organization, the
U.S. Food and Drug Administration, the Italian Society of Pharmacology, and the Centers for Disease
Control and Prevention (CDC). Furthermore, we have identified more than 100 articles that use two
primary sources to classify relevant information: PubMed and SCOPUS (the latest access of PubMed
and SCOPUS in March 2020).
2.1. Transmission
In the case of COVID-19, as reported by the World Health Organization (WHO) “Situation
Report—12”, the modality of transmission can be similar to the previous epidemics caused by other
coronaviruses (MERS, Middle Eastern Respiratory Syndrome, and SARS, Acute Respiratory Syndrome),
for which human-to-human transmission occurrs through droplets, aerosols and direct contact [18].
In particular, the droplets, generated during speaking, coughing and sneezing by symptomatic
patients, can spread up to 1–2 m; a recent study demonstrated that the infection can also occur from
asymptomatic people and before the onset of symptoms [19].
Another mode of transmission is enabled by the inhalation of aerosols, which are microparticles
with a diameter smaller than 5 µm, containing pathogens, which after having been released in the air,
are transported by the flow of the air current, thus being able to cause diffusion even at a considerable
distance (with reverse ratio due to their dilution) (Figure 1) [20]. Currently, the literature cannot
give information on the practicable concentration of SARS-CoV-2 to infect a human being; however,
it has been quantified that SARS-CoV-2 remains practicable in aerosols after 3 h, with a reduction
in the infectious titer from 103.5 to 102.7 TCID50 per liter of air. This reduction was similar to that
observed with SARS-CoV-1, from 104.3 to 103.5 TCID50 per mL. The half-life of the viable virus was
also estimated for aerosol based on estimated exponential decay rates of the virus titer in approximately
1 h [21].
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Figure 1. Transmission ways of COV-19.
Finally, SARS-CoV-2 can also be transmitted through direct or indirect contact with infected
people or by depositing droplets containing the virus on any person (handshake, greeting, hug) or
inanimate surface [22]; these droplets can contaminate the hands of other subjects by subsequently
entering the body through access routes such as the oral cavity, the nasal cavity, the eyes and other
mucous membranes (Figure 1) [20].
There are no studies in the literature that demonstrate in practice a vital concentration of
SARS-CoV-2 necessary to infect a human being from inanimate surfaces. Instead, it has been shown
how the half-life of SARS-CoV-2 varies on different surfaces such as plastic, stainless steel, copper and
cardboard (Table 2) [21].
Table 2. Conditions of 21–23 ◦C and 40% relative humidity over 7 days [21].
SURFACE MATERIAL TITER OF VIABLE VIRUS THE HALF-LIFE OF VIABLE VIRUS
Stainless steel 48 h 5 h
Plastic 72 h 7 h
Copper 8 h 1 h
Cardboard 48 h 3 h
2.2. Epidemiology
The epidemiological data related to SARS-CoV-2 infection are constantly evolving and are daily
updated in the coronavirus disease (COVID-19) situation report of the WHO [23].
According to a first study conducted in Wuhan, on a small cohort of 99 subjects, the infection
was more likely to affect older males with comorbidities, in whom it induced the appearance of
symptomatic episodes of serious or even fatal respiratory pathologies such as the acute respiratory
distress syndrome [24].
The data was confirmed by the major epidemiological study conducted by the Chinese Centre for
Disease Control and Prevention, which found that the mortality rate grew from 0.2% in patients aged
between 10 and 39 years to 14.8% in those over 80, and that the risk of death is greater among men
(2.8%) than among women (1.7%).
Another lethality factor has been identified in the simultaneous presence of pre-existing diseases,
especially cardiovascular ones, metabolic pathologies such as diabetes, chronic respiratory failure
and hypertension.
However, among those who are in perfect health at the time of infection, the mortality rate is 0.9%.
Furthermore, it has been shown that 80.9% of infections have no symptoms or a mild course, 13.8%
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severe, while 4.7% of those infected developed critical pathological symptoms with symptoms such as
respiratory failure, septic shock or multi-organ failure [25].
2.3. Testing and Pharmacological Approach
Appropriate and specific diagnostic techniques are important to detect the presence of the
SARS-CoV-2 virus in the human body early. Although many laboratory tests have been implemented,
nowadays, screening protocols should be adapted to the local situation and the guideline reviewed
and update on the basis of the last information available.
In this regard, the World Health Organization reviewed and published a paper containing
guidelines to follow and practice. Together, along with the ordinary tests, these provide further and
specific information about the real existence of this specific virus in the samples analyzed [26].
In detail, we should proceed following different strategies in relationship to the individual. In
particular, to assess the individuals who have had contact with a COVID-19 case, we can use the PCR
test, which works by detecting specific genetic material within the virus. Depending on the type of
PCR on hand, health care workers might swab the back of the throat; take a saliva sample; collect a
liquid sample from the lower respiratory tract; or secure a stool sample. Furthermore, suspected cases
should be screened for the virus with nucleic acid amplification tests (NAAT), such as the real-time
reverse transcription polymerase chain reaction (rRT-PCR) test, specific for the qualitative detection
of nucleic acid from SARS-CoV-2 in upper and lower respiratory specimens such as nasopharyngeal
or oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and
nasopharyngeal wash/aspirate or nasal aspirate [27]. Until now, serologic tests for COVID19 have not
been developed [28].
At present, there are no specific treatments for infections caused by coronavirus and there
are currently no vaccines available to protect us against these viruses. Most people with common
coronaviruses heal spontaneously or are treated on the basis of the severity of their symptoms, either
with conventional antiviral therapies (so called supportive therapy) or by providing mechanical
respiratory support.
A variety of drugs already in use and experimental drugs likely to be useful for the treatment of
COVID-19 patients have been identified in recent months. The screenings of the drugs approved by
the National Medical Products Administration (NMPA) and other chemical entities have identified
different agents.
Several clinical trials have been recently scheduled to take into consideration drugs with different
mechanisms of action for the treatment of COVID-19 patients. Remdesivir [29], an antiviral drug
already used for the treatment of Ebola [30], is a compound with a broad spectrum of antiviral
activities [29,31–33]. In particular, this drug showed a good antiviral activity in both in-vitro and in-vivo
studies of animal models against various RNA viruses genetically unrelated but similar to SARS-CoV-2,
such as SARS-CoV and respiratory syndrome coronavirus of the Middle East (MERS-CoV) [34–37].
These studies provide further insight on the action of Remdesivir against coronaviruses, making it a
promising agent for the treatment of COVID-19, in association with chloroquine.
Chloroquine, an agent already used as an anti-malarial drug and which has also been studied for
its use in pulmonary system disease [38,39]; has been shown to be effective in SARS-CoV-2 infection
in in-vitro experimental models. The antiviral action of this drug is attributed to its capacity to alter
(increase) the endosomal pH, which is fundamental for virus–cell fusion, as well as to the interference on
the glycosylation of SARS-CoV-2 cell receptors. Furthermore, it has been reported that chloroquine may
be also able to block the viral replication of SARS-CoV-2 at usable doses in humans [34,40]. According
to a recent study, hydroxychloroquine may be active against SARS-CoV-2 at lower concentrations than
chloroquine. In addition to the antiviral action, these drugs have an immunomodulation activity that
could synergistically enhance the antiviral effect in vivo [41].
Another antiviral drug object of studies for the treatment of COVID-19 is favipiravir. The
drug has been used off-label in other countries to treat infections with new viruses including Ebola
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and, more recently, it was approved in China for the treatment of flu by SARS-CoV-2. This agent,
administered as prodrug, performs its antiviral action through its active metabolite favipiravir
ribofuranosyl-5I-triphosphate [28]. It acts as an antiviral agent capable of inhibiting RNA-dependent
RNA polymerase (RdRp) of RNA viruses [42]. In particular, it is a nucleoside analog, whose antiviral
activity may be attributable primarily to its incorporation into viral RNA, which in turn exerts
mutagenic activity in viruses, causing their death.
Besides antiviral agents, in recent days, other drugs are under investigation for the therapy
of COVID-19. This includes tocilizumab, a humanized monoclonal antibody that binds and
neutralizes IL-6R, resulting in the inhibition of various IL-6-mediated biological activities, including
inflammation-related, immunomodulatory rheumatoid arthritis (RA) and systemic juvenile idiopathic
arthritis, and the treatment of cytokine release syndrome induced by chimeric antigen receptor
(CAR)-modified T cells. This agent is indicated for use off-label, in patients with infection of
SARS-CoV-2. The rationale of its employing it is based on the evidence that COVID-19 infection induce
an excessive and aberrant immune system response also associated with acute respiratory distress
syndrome and, in most critically ill patients, with a “cytokine storm” (increased plasma and tissue
levels of various cytokines that produce long-term damage and fibrosis of lung tissue) [43].
In the last days, different groups of researchers [44,45] have focused their attention on the role
played by the angiotensin-converting enzyme 2 (ACE2) as a possible target for the treatment of
SARS-COV-2. In detail, there are two different forms of ACE2 enzyme. The first one is known
as full-length angiotensin-converting enzyme 2 (ACE2), and contains a structural transmembrane
domain, able to mediate SARS-CoV-2 cell attachment and its subsequent fusion with membranes
of lung cells [46,47]. The second one is a soluble circulating form, which lacks the domain portion
able to anchor to cell membrane. In-vitro studies showed that this form binds the virus, making it
impossible for it to fuse with cells. Through its mechanism of action, soluble recombinant ACE2 protein
could play a prominent role in the new pharmacological approach for attenuation or eradication
of COVID-19 [44,45,48,49]. Unfortunately, at the moment, there is limited research on the potential
beneficial effect of the drugs reported above. On the other hand, the evaluation of drugs suitable for
COVID-19 therapy requires adequate studies, randomized with realistic eligibility criteria and which
would consider an adequate stratification of patients for clinical trials. Rapid completion of these
studies is important in order to identify effective drug therapies.
3. Prevention and Protection
3.1. Organizational Measures
General organizational measures regarding the containment and management of the
epidemiological emergency of COVID-19 have been imposed by the competent authorities for an
adequate and proportionate management of the evolution of the epidemiological situation.
The prevention and protection organizational measures therefore aim to minimize the probability
of being exposed to SARS-CoV-2. For this purpose, measures must be taken to avoid new infections or
even the spread of the virus where it has already been present.
It is therefore useful for companies in which various persons come and go during the day to
reduce visitors’ entry strictly to the minimum, also limiting access to all subjects, including employees.
They should also block persons with obvious flu-like symptoms, and census the employees who are
allowed to enter.
In the case of the presence of travelling staff, they should be prevented from travelling in countries
which are sensitive to SARS-CoV-2, in the so-called red areas; companies should apply a quarantine
measure with active surveillance of those who have had close contacts with people affected by
COVID-19, and the provision of the obligation for those coming from areas at risk of epidemiology to
communicate it to the prevention department of the competent health company, in order to enable an
eventual fiduciary home stay measure with active surveillance [50].
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The measures to be taken are:
• Blocking all trips to and from all areas defined as “red”, in which cases of COVID-19 infections
have already been ascertained.
• Possible 14-day home quarantine for those who live, work or return from these areas.
• Selective control and measurement of body temperature of all suppliers and external collaborators.
• Reduction of the number of operators within each confined environment.
• Prioritize, where possible, work from home (smart working).
• Composing, if possible, two or more closed and independent working groups, to be alternated
every 14 days to work in the company or in smart working.
• Predisposition and maximum adherence to PPE dressing and undressing protocols.
3.2. Environmental Measures
Environmental measures are aimed at reducing the risk of transmission of SARS-CoV-2 infection
to individuals through contact with infected subjects, with objects, equipment, or contaminated
environmental surfaces.
Even if there are no disinfectants registered specifically as active on SARS-CoV-2, viruses with
similar biochemical and physical properties are inactivated with detergents and disinfectants commonly
used in hospitals; this ensures a low or intermediate disinfection, following the manufacturer’s
instructions and the technical data sheet regarding dilution, contact time and handling [51].
In the literature, various evidence has shown how coronaviruses, including the viruses responsible
for SARS and MERS, can persist, in optimal conditions of low humidity and low temperature [52], for
up to 9 days on the inanimate surfaces of all shared rooms, especially bathrooms, changing rooms,
canteens, rooms with distributors, smoking areas, and offices shared with several people. A role of
contaminated surfaces in the transmission of SARS-CoV-2 infection is therefore to be considered as
being possible, even if not yet demonstrated [53].
At the same time, available evidence has shown that the aforementioned viruses are effectively
inactivated by adequate sanitization procedures, which include the use of disinfectants based on
sodium hypochlorite (0.1%–0.5%), ethanol (62%–71%) or hydrogen peroxide (0.5%), for an adequate
contact time, providing adequate ventilation of closed rooms [54]; or through the use of physical means
such as ultraviolet irradiation (UV) [55]. Therefore, extraordinary cleaning and sanitization procedures
must be adopted using the appropriate disinfectants/disinfectants (Table 3) and remembering to pay
the utmost attention to the removal of any organic residues, intensifying the frequency with which
these activities are normally carried out.
Table 3. List of disinfectants active on viruses and their related areas of application.
DISINFECTING SUBSTANCE APPLICATION SCOPE
Alcohol Cutaneous antisepsisDisinfection of small surfaces
Chlorine compounds (chloramine, hypochlorite) Cutaneous and wound antisepsisWater treatmentSurface disinfection
Glutaraldehyde Disinfection of inanimate objects
Hydrogen peroxide Cutaneous antisepsis
Iodophors Skin and wound antisepsis
Acetic acid Disinfection of inanimate objects
There are currently no studies on the effects of temperature and relative humidity on the viability of
SARS-CoV-2 in the literature, but, similar to the effects on SARS-CoV-1, for which there are documents
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demonstrating these effects, we can suggest that it is useful keep the confined spaces very airy, ensuring
inside them a temperature of over 20 degrees and with a degree of humidity higher than 60% [56].
Reduce close contacts between work colleagues or other staff by applying these recommendations:
• Reduce direct physical contact (for example, shake hands);
• Avoid direct unprotected contact with secretions (esp. coughing, touching used paper tissues
with bare hands);
• Avoid direct contact within 2 m and >15 min;
• Reduce contact with people in a closed environment (esp. classrooms, meeting rooms, hospital
waiting rooms, etc.) beyond 15 min and at a distance of less than 2 m [57,58].
Finally, a suitable isolation room must be identified and prepared to bring any suspicious cases
pending verification by the NHS. This isolation room must be kept clean and ventilated, and, after its use,
sanitized with the removal of all organic and inorganic residues through a suitable disposal procedure.
3.3. Personal Measures
3.3.1. Hand Washing
Proper hand washing is the essential measure to prevent the transmission of SARS-CoV-2.
Hands should be washed with soap and water for at least 40–60 s; if soap and water are not
available, a 62%–71% alcohol-based hand disinfectant can also be used (Figure 2).
Figure 2. Correct procedure for washing hands.
Hands must be washed:
• Before starting work, especially if this involves contact with the public;
• Frequently during the work shift, especially after contact with other staff or customers;
• After contact with secretions, excretions, biological liquids;
• After contact with potentially contaminated objects (gloves, clothing, masks, used tissues, waste);
• Immediately after removing gloves and other protective equipment.
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Also remember to avoid close contact with people who suffer from acute respiratory infections by
keeping at least one meter away, especially when they cough or sneeze or have fever.
Do not touch your eyes, nose, mouth or genitals, with your hands before having thoroughly
washed and sanitized them. Although SARS-CoV-2 is mainly transmitted by the respiratory way, it can
also enter the body through the mucous membranes; hands coming into contact with contaminated
surfaces can act as a carrier.
Cover your mouth and nose if you sneeze or cough, remembering not to use the hand for this
purpose but the crease of the forearm [58].
3.3.2. Personal Protective Equipment (PPE)
Gloves
Use devices that comply with the requirements of the technical standard EN 374, classified as
third category PPE for protection from microorganisms (a CE certification must have been issued by
the notification body for the manufacturer certifying the CE marking as PPE) [59].
The disposable protective nitrile gloves are made of a composition based on butadine and
acrylonitrile, which give it the characteristics of high comfort, ergonomics, elasticity and mechanical
resistance, both to perforation and also if put in contact with some chemical substances. Finally, their
hypoallergenic characteristic compared to latex gloves should not be underestimated.
Indications for the use of gloves:
• Must be clean gloves and they must cover the wrist well;
• Must be removed immediately after completing the procedures that they were used for; in
particular, great care must be taken not to touch clean surfaces with contaminated gloves;
• Must be absolutely changed if dirty or not perfectly intact;
• Glove decontamination prior to glove removal with hypochlorite [60], after every contact with
different inanimate surface, and during doffing procedures;
• Must not be reused or washed.
Disposable Masks/Respirators
Respiratory particles can be classified as droplets or aerosols based on the size of the particles
and in particular in terms of their aerodynamic diameter. The World Health Organization (WHO) and
the Centers for Disease Control and Prevention (CDC) consider the transmission of the disease with
particles larger than 5 microns as a transmission via droplets, while in the case of a size of 5 microns or
less as an aerosol transmission [61].
Both types of particles, droplets and aerosols, are generated by coughing, sneezing, speaking or
simply exhaling; while droplets settle quickly, small aerosols can remain suspended in the air and can
be transported over long distances by the air flow.
Compared to droplets that cause infection at a distance of less than one meter, aerosols can cause
contagion at greater distances, but with a ratio inversely proportional to the space covered and the
dilution suffered.
Filter Masks
The principle on which these masks are based is to adhere to the face by creating a slightly negative
pressure inside the mask and thus filtering the incoming air.
In order for these devices to actually protect those who use them, it is essential to plan and
implement a training program related to the use of them.
According to the American NIOSH regulations, the N95 masks must be used in environments
potentially contaminated with SARS-CoV-2 (with a filtering capacity of at least 95%, a leakage of 10%,
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a bacterial filtration efficiency of 99%). However, according to the European legislation, the masks that
are closest to these standards are FFP2 and FFP3.
The average filtering power offered by respirators with an N95 facial filter against particles in
the range of tested sizes is about 8–12 times greater than that provided by disposable surgical masks,
whose filtering powers varied widely in the various studies, depending on the model and size of the
aerosol particles (1.3 to 6.5 µm). This result is superimposable to that obtained by other studies, which
claim that the protection provided by respirators with an N95 facial filter is approximately seven times
greater than that of surgical masks [62].
The N95 respirators with an exhalation valve are designed to facilitate breathing. The results of
the literature analyzed by us have shown that the respirator with an N95 facial filter and exhalation
valve does not lose its ability to protect the wearer from exposure to airborne particles in the range
of bacterial and viral dimensions. The aerosol penetration through the exhalation valve was also
studied for negative pressure respirators, reaching the conclusion that the penetration values were
about 0.03%–0.04% with no valve fault [62,63].
Disposable Surgical Masks (Facemasks)
Facemasks (surgical masks), with disposable fabric or not, are formed by four layers (type II or
IIR): external, which is filtering; central, which is impermeable to liquids but air permeable; the internal
layer, which is in contact with the hypoallergenic skin, with upper deformable nose bar to conform
perfectly the face mask and with fastening system formed of ties or elastic bands.
They protect the nose and mouth from contamination with particles with an average diameter
of 4.5 µm [64]. While originating from the need to protect the patient (surgical interventions, aseptic
maneuvers), they constitute an effective barrier system for potentially infected liquids even for those
who use them.
The use of the surgical mask is recommended:
• For those who work in contact with subjects with suspected airborne disease (flu syndrome,
chicken pox, measles);
• In activities for which there is the possibility of generating splatters or splashes of blood or other
body fluids;
• In technical and administrative support activities;
• By doctors, nurses, biologists, midwives and all healthcare personnel;
• By the staff of contracting firms (e.g., cleaning);
• By public assistance staff.
Data indicate that a surgical mask reduces virus exposure 1.1 to 55 times (on average six times),
depending on the mask design [64]. They are currently indicated to be worn by the potentially
infected subject.
Disposable surgical masks can confer a significant degree of protection, although less strong than
FFP2 masks. However, surgical masks suffer less from limited supplies and do not need additional
resources to supply on a large scale. Surgical masks are unlikely to confer much protection against the
transmission of small particles such as droplet nuclei, but a partial reduction in the transmissibility
of the virus may be sufficient to greatly reduce the number of infected and therefore to counter the
pandemic [65].
Indications on the use of the facemasks:
Of course, no mask, be it the tight-fitting NIOSH-approved N95 respirator mask or the loosely
worn surgical mask, provides perfect (100%) protection. But imperfect protection does not mean
“completely useless” [66].
FFP2 and FFP3 filtering masks should be provided for all personnel, to be distributed and used
after a training program; therefore, in this regard, the personnel must:
• Read the manufacturer’s instructions to verify the correct adhesion of the facial filter;
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• Wear the mask, taking care that there are no structural alterations;
• Check adhesion by exhaling (if the mask has an exhalation valve) or inhaling (if the mask does
not have an exhalation valve), thus checking for any abnormal passage of air.
In case of difficulty in finding the filter masks described above, surgical disposable masks can
be used; even if with the limitations related to the imperfect adherence to the face, depending on the
different design of the models on the market; these devices are to some extent protective, above all in
preventing close contact with droplets, and even more effective if associated with other PPE (nitrile
disposable gloves, protective glasses).
Safety Goggles and Splash Guard Visor
The conjunctiva is susceptible to the entry of microorganisms. For this reason, it is important to
protect the eyes from exposure to SARS-CoV-2 when in close contact with an infected person.
These PPE must possess the certification issued by the notification body for the manufacturer
as regards the CE marking as PPE for the “protection against splashing liquids” according to the
requirements of the technical standard EN 166, elaborated for this purpose [67].
Devices for which the certifications of compliance with the aforementioned technical standard
also certify the “protection from droplets” are preferred.
Visors are not able to be used if an FFP2 mask is worn. Therefore, in the procedures that involve
splashes, goggles that guarantee protection from droplets must necessarily be provided.
These protective devices must be used whenever there is potentially close contact with a suspect
case, especially when the potentially infected person does not wear a surgical mask that could reduce
the spread of viruses in the environment.
It is important to decontaminate them after having been used, as they can act as a SARS-CoV-2
transmission vector themselves.
All the PPE described above must be removed and disposed of by following the correct procedures
by the wearer. Correct removal is essential to prevent recontamination of the wearer’s clothes or hands.
Here is the recommended sequence for safely removing PPE:
• Removing the gloves by rolling them down from the wrist, without touching the skin;
• Removing the protective clothing, being careful to fold it with the contaminated external part
inside and disposing of it in a container with a lid;
• Hand washing;
• Removing the safety goggles or the splash guard goggles;
• Removing the facemask/respirator, taking care to touch only the strings and not the contaminated
surface, and disposing of it in a container with a lid.
In the event of the identification of a potentially infected person, the following measures must be
applied while awaiting the health care personnel:
• Avoid close contact with the sick person; if possible, accompany the subject in the isolation room
especially prepared;
• If available, provide the person with a surgical facemask and disposable nitrile gloves which he
must put on by himself;
• Wash your hands thoroughly;
• Pay particular attention to the body surfaces that have possibly come into contact with the patient’s
fluids (respiratory secretions, urine, faeces);
• Have the subject eliminate, directly in a waterproof bag, both the masks and the gloves, as
well as any used paper tissues. The bag will then be disposed of in an appropriate manner,
together with the infected materials used during the medical assistance procedure offered by the
healthcare personnel.
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Isolation Gowns
Disposable (single-use) isolation gowns are designed to be discarded after a single use and are
typically constructed of nonwoven materials alone or in combination with materials that offer increased
protection from liquid penetration, such as plastic films. They can be produced using a variety of
nonwoven fiber-bonding technologies (thermal, chemical, or mechanical) to provide integrity and
strength rather than the interlocking geometries associated with woven and knitted materials [68].
4. Discussion
The recommendations set out so for the prevention of COVID-19 far in the workplace (Table 4)
can be implemented by integrating the information based on the degree of the spreading risk of this
virus in the company, determined by its location in relation to the areas of greatest risk and by the type
of work carried out, as suggested by the Guidance on Preparing Workplaces for COVID-19 [69,70].
Our proposal for risk classification is:
• Companies with a low probability level of infection spreading:
# Located in areas where there are no reported cases of disease contamination in the
entire province;
# With a maximum of 10 employees;
# Which mainly carry out office activities with a limited flow of customers.
• Companies with a medium probability level of infection spreading:
# Located in areas where there are reported cases of disease contamination in the province;
# With a maximum number of 50 employees;
# Which mainly carry out commercial activities;
# Which expose employees to sporadic contact with customers.
• Companies with a high probability level of infection spreading:
# Located in areas in which in the neighboring cities or in the same city of the workplace,
there are clear cases of disease contamination;
# With a maximum number of over 50 employees;
# Which carry out front-office activities in continuous contact with customers;
# With travelling staff;
# Which operate in the health sector.
• Companies with a very high probability level of infection spreading
# Very-high-exposure-risk jobs are those with high potential for exposure to known or
suspected sources of COVID-19 during specific medical, post-mortem, or laboratory
procedures. Workers in this category include:
 Healthcare workers (doctors, nurses, dentists, paramedics, emergency medical
technicians) performing aerosol-generating procedures (e.g., intubation, cough
induction procedures, bronchoscopies, some dental procedures and exams, or
invasive specimen collection) on known or suspected COVID-19 patients.
 Healthcare or laboratory personnel collecting or handling specimens from known
or suspected COVID-19 patients (manipulating cultures from known or suspected
COVID-19 patients).
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Table 4. Summary of the prevention and protection measures proposed according to the risk level.
RISK L. ORGANIZATIONAL MEASURES ENVIRONMENTAL MEASURES INDIVIDUAL MEASURES
Low
• Informing all employees about the risk.
• Strict control over external access (suppliers, contractors,
customers), to limit contacts with their employees to
a minimum.
• Selective control and measurement of body temperature
of all suppliers and external collaborators.
• Take extraordinary cleaning and sanitization measures,
using the appropriate disinfectants/sanitizers.
• Cleaning at the end of shift of keyboards, touch
screens, mouse and inanimate surfaces
• Reduction of the number of people inside the same
room, considering a density of 1 person every
10 square meters.
• Keep a distance of 2 m between 2 or more people.
• Hand washing with soap or hand sanitizer
Medium
All measures indicated for the previous level
• Limitation to the bare minimum of front-office activities
with external users
• Evaluation of the concession of working methods such
as smart-working
• Blocking all journeys to and from all areas defined as
“red”, in which cases of COV-19 infections have already
been ascertained,
• Possible 14-day home quarantine for those who live, work
or return from these areas;
• Composing, if possible, two or more closed and
independent working groups, to be alternated every 14
days to work in the company or in smart working
All measures indicated for the previous level
• Indoor temperature >20 ◦C, indoor humidity >60%.
• Adopt extraordinary cleaning and sanitizing
procedures for all shared rooms, in particular:
bathrooms, changing rooms, canteens, rooms with
distributors, smoking areas, offices shared with
several people
• Preparation of special bins for the collection of gloves,
clothing, masks, used handkerchiefs, waste and other
similar contaminated materials with biological liquids,
to be disposed of as biological waste
All measures indicated for the previous level
• Use of disposable nitrile gloves by workers who
have to interact with shelf materials/products,
permanently exposed to customers.
• Provide, only to workers involved in front-office
activities, filtering face masks of type FFP2 or
FFP3, after having been informed on their use.
• In case of difficulty in finding the aforementioned
filtering face masks, make available disposable
surgical masks.
High
All measures indicated for the previous level
• Assessing the possibility of suspending the activity,
within the limits of the law and without prejudicing the
free entrepreneurial initiative in the private sector, and the
execution of essential and public utility services in the
public and private sectors.
All measures indicated for the previous level
• Increase the frequency of cleaning and sanitizing of
the premises.
• Identify and prepare a suitable room for the isolation
of any suspicious cases pending verification by
the NHS.
All measures indicated for the previous level
• Frequent hand washing and sanitizing.
• Provision of masks, as described in the previous
scenario, for all workers.
• Provision of safety goggles (measure necessary in
the health sector).
• Glove decontamination with hypochlorite after
every contact with different inanimate surface, and
during doffing procedures.
Very high
All measures indicated for the previous level
• Predisposition and maximum adherence to PPE dressing
and undressing protocols
All measures indicated for the previous level
• Ensure appropriate air-handling systems are installed
and maintained in healthcare facilities.
• The work area must be kept at a negative pressure
compared to the atmospheric one
• Sanitization of the premises through the use of
physical means such as ultraviolet irradiation (UV).
All measures indicated for the previous level
• Provision Isolation gowns
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Morgue workers performing autopsies, which generally involve aerosol-generating procedures,
on the bodies of people who are known to have, or suspected of having, COVID-19 at the time of their
death [70].
5. Conclusions
An outbreak of corona virus was recognized in early January 2020 in Wuhan, China. This virus
has been spreading throughout China for at least two months and has been exported to at least 180
more other countries [71,72]. The virus has been named SARS-CoV-2 and the disease has been named
COVID-19 (Coronavirus Disease 2019).
Considering the lack of knowledge about how and by whom SARS-CoV-2 is transmitted, our goal
was therefore to develop a guide on the application of preventive and protective measures, useful in
the workplace, for all activities that involve a relationship with both customers and colleagues, after
analyzing the latest publications on SARS-CoV-2 and the other coronaviruses and on the prevention of
respiratory diseases.
Among the organizational, environmental and personal preventive measures, as shown in Table 3,
the control of the physical conditions, by detecting the temperature, and of flu-like symptoms of the
workers, considering that the period of maximum infectivity is the symptomatic one, is a rule that also
in the future can be used as an effective preventive measure for any subsequent endemic SARS-CoV-2
waves. Composition, when it is possible, of two or more closed and independent work groups, to be
alternated every 14 days to work in the company or in smart working, could help the company to
isolate only one group in case of infection and quarantine.
We considered the same for PPE, considering the way in which its use, even in the absence of
scientific evidence, prevents the main transmission routes used by the virus through the large droplets
emitted with speaking, coughing and sneezing, and through inanimate surfaces.
For this purpose, the combined use of respiratory mask, protective visor and gloves constitutes a
useful mechanical barrier to be adopted in work activities where it is not always possible to maintain
the recommended safety distances.
For donning and doffing procedures, following CDC doffing guidance, one-step glove and gown
removal, double-gloving, spoken instructions during doffing, and use of glove disinfection with
hypochlorite may reduce contamination and increase compliance [60–73].
By adopting these organizational, environmental and personal measures, emergency management
can be optimized, ensuring the continuation of normal activities and ultimately contributing to reducing
the risk of contamination of the workforce and the entire population.
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